Evidence map›Paper›PMID 23326573›Full record

ArticlePloS one2013

An assay suitable for high throughput screening of anti-influenza drugs.

Lili Mao, Jun Wang, William F DeGrado, Masayori Inouye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. A bacteria-based search for drugs against avian and swine flu yields a potent and resistance-resilient channel blocker.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lili MaoDepartment of Biochemistry and Center for Advanced Biotechnology and Medicine, Robert Wood Johnson Medical School, Piscataway, New Jersey, United States of America.
Jun Wang
William F DeGrado
Masayori Inouye

Funding

Development of drugs that target the M2 proton channel from the influenza A VirusU01AI074571 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DEGRADO, WILLIAM · 2008 to 2012
$7.5M
Structure of M2 Proton Channel from Influenza A VirusR01GM056423 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI DEGRADO, WILLIAM · 1997 to 2016
$4.5M
The Method for Determination of Membrane Protein Structures without Purification R01GM085449 · NIGMS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI INOUYE, MASAYORI · 2008 to 2011
$1.2M
NIAID NIH HHS AI074571NIAID NIH HHS U01 AI074571NIGMS NIH HHS 1R01GM085449NIGMS NIH HHS R01 GM056423NIGMS NIH HHS R01 GM085449
6 · The paper itself

Abstract

We developed a novel drug screening system for anti-influenza A virus by targeting the M2 proton channel. In the SPP (Single Protein Production) system, E. coli cell growth occurs only in the presence of effective M2 channel inhibitors, and thus simple measurement of cell growth was used as readouts for drug screening. Two potential inhibitors for M2 (V27A) mutant were verified using this method, which inhibit both the mutant and wild-type M2 channels.

Indexed as

Escherichia coliInfluenza A virusAntiviral AgentsDrug Evaluation, PreclinicalDrug Resistance, ViralGene Expression Regulation, BacterialHigh-Throughput Screening AssaysHumansInfluenza, HumanMutationRecombinant ProteinsViral Matrix ProteinsViroporin ProteinsAntiviral AgentsM2 protein, Influenza A virusRecombinant ProteinsViral Matrix ProteinsViroporin Proteins

Identifiers

PMID23326573
PMCPMC3542334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.